Monopar Appoints Jeffrey D. Kent, M.D.

WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs, effective September 1, 2026. The Company also announced that two abstracts on ALXN1840 (tiomolibdate choline, TMC), its late-stage candidate for the treatment of Wilson disease, have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026, taking place November 5-9, 2026, in Denver, Colorado.

GlobeNewsWire • Aug 19, 2026

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'

Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for ALXN1840 in the coming months is a major catalyst, with potential FDA approval and Priority Review Voucher upside. ALXN1840 demonstrated statistically significant efficacy in phase 3, showing 3x copper mobilization over placebo and notable neurological improvement versus standard of care.

Seeking Alpha • Aug 18, 2026

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

WILMETTE, Ill., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced second quarter 2026 financial results and provided business updates.

GlobeNewsWire • Aug 12, 2026

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that it has initiated the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ALXN1840 (tiomolibdate choline, TMC), its first-in-class albumin tripartite complex (“ATC”) activator for the treatment of Wilson disease. The FDA has authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections. Monopar has submitted the first completed sections of the NDA.

GlobeNewsWire • Jul 22, 2026

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

WILMETTE, Ill., July 20, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the addition of seasoned commercial leaders to support the anticipated launch of the Company's first commercial product, ALXN1840, pending U.S. Food and Drug Administration (FDA) approval.

GlobeNewsWire • Jul 20, 2026

Monopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)

I initiate coverage of Monopar Therapeutics with a BUY rating, targeting $145 per share based on ALXN1840's probability-adjusted commercial potential. ALXN1840 demonstrated significant neurological benefit and copper mobilization in Wilson disease, with an impressive NNT of six and strong Phase 3 data. My valuation assumes $750M in global peak sales, an 80% probability of success, and a robust cash runway through 2027, supporting regulatory and commercial milestones.

Seeking Alpha • Jul 17, 2026

Monopar Therapeutics: ALXN1840's Bull Case Has Improved

Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer regulatory path, FDA designations, and even a possible Priority Review Voucher. MNPR's financing also seems safer this time around as they prepare ALXN1840's NDA and subsequent potential launch.

Seeking Alpha • Jul 3, 2026

Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease

WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Company's late-stage candidate for the treatment of Wilson disease.

GlobeNewsWire • Jun 30, 2026

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

GlobeNewsWire • Jun 26, 2026

Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade

The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • Jun 15, 2026